Datapoint: FDA Delays Decision on Reblozyl Label Expansion

The FDA has delayed its review of Bristol Myers Squibb and Merck’s Reblozyl for anemia from non-transfusion-dependent beta thalassemia until late June, according to a news release from BMS. The agency said it needs the extra time as a “written response to an information request was determined by the FDA to constitute a major amendment,” though BMS did not reveal what the information request entails. For the treatment of transfusion-dependent anemia-associated beta thalassemia, Reblozyl holds covered or better status for 58% of all insured lives under the pharmacy benefit. Under the medical benefit, 83% of all insured lives have covered or better access to Reblozyl.

SOURCE: MMIT Analytics, as of 3/30/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today